arrow_rightarrow_righticon_excelicon_pficon_ppticon_wordmagnifier

Tuesday 3 July 2018

Tuesday 03 Jul

09:00

Plenary session: The evolving role of infection control in mycology

Andreas Voss, the Netherlands

10:00

Break

10:30

Parallel session VII

Parallel session VII will take place from 10:30 hrs. until 12:00 hrs. and consists of seven symposia.

S7.1 Fungal biofilms

Convener: Gordon Ramage, United Kingdom

10:30

S7.1a Candida auris and non-albicans biofilms

Gordon Ramage, United Kingdom

10:55

S7.1b insights into new antibiofilm molecules

Jose Lopez-Ribot, USA

11:20

S7.1c Induction of trained innate immunity against fungal/bacterial sepsis

Mairi Noverr, USA

11:45

S7.1d Deciphering the global transcriptomic profile of Candida glabrata during biofilm and planktonic growth phase

Kem Raj, India

S7.2 Fungal Interactions with Epithelium Trigger Innate Immune Activation

Convener: Andrew Limper, USA

10:30

S7.2a Epithelial Activation by Candida species

Julian Naglik, United Kingdom

10:55

S7.2b The Immunopathogenesis of Candida Vaginitis

Paul Fidel, USA

11:20

S7.2c Pneumocystis Activation of Innate Immune Responses by Lung Epithelial Cells

Andrew Limper, USA

11:45

S7.2d Differential gene expression of Aspergillus fumigatus and Aspergillus niger interacting with epithelial lung cells

Esther Keizer, the Netherlands

S7.3 The Real Pathogens: Ajellomycetaceae

Convener: Anastasia Litvintseva, USA

10:30

S7.3a Emerging Emergomyces africanus in Africa

Nelesh Govender, South Africa

10:55

S7.3b Migration of Coccidioides posadasii into South America

Bridget Barker, USA

11:20

S7.3c Ecology and geographic distribution of Coccidioides

Anastasia Litvintseva, USA

11:45

S7.3d Molecular epidemiology of Colombian Histoplasma capsulatum (Hc) isolates showed their polyphyletic behavior and indicated chicken manure as one infection source

Luisa Gómez Londoño, Colombia

S7.4 Why do patients get aspergillosis?

Convener: Adilia Warris, United Kingdom

10:30

S7.4a Influenza-associated aspergillosis

Frank van Veerdonk, the Netherlands

10:55

S7.4b Aspergillus-derived secreted products driving invasion of pulmonary epithelia

Elaine Bignell, United Kingdom

11:20

S7.4c Defective antifungal immunity in cystic fibrosis

Adilia Warris, United Kingdom

11:45

S7.4d Increased incidence of invasive aspergillosis in patients receiving empiric carbapenem in febrile neutropenia

Chai Louis, Singapore

S7.5 Scedosporium

Conveners: Sharon Chen, Australia & Michaela Lackner, Austria

10:30

S7.5a Enzymatic antioxidant defense systems in Scedosporium species

Jean-Philippe Bouchara, France

10:55

S7.5b N-chlorotaurine, a potential agent for the topical treatment of scedosporiosis and lomentosporiosis

Michaela Lackner, Austria

11:20

S7.5c Diversity within the genera Lomentospora and Scedosporium

José Cano, Spain

11:45

S7.5d “S.O.S.”: The Nationwide French Scedosporiosis Observational Study (2005-2017)

Franny Lanternier, France

S7.6 Sporothrix WG

Convener: Leila Lopes-Bezerra, Brazil

10:30

S7.6a RNA-seq and transcriptome-wide analysis of Sporothrix schenckii yeast and mycelial forms

Orazio Romeo, Italy

10:55

S7.6b Soprothrix globosa causing sporotrichosis in Jilin Province (Northeast of China):Prevalence,Molecular Characterization,and Antifungal Susceptibility

Shanshan Li, China

11:20

S7.6c Human serum factors impact the interaction of Sporothrix spp. with human macrophages

Leila Lopes Bezerra, Brazil

11:45

S7.6d Cutaneous disseminated sporotrichosis: Clinical experience of 24 cases

Alexandro Bonifaz, Mexico

S7.7 Pediatrics

Convener: Andreas Groll, Germany

10:30

S7.7a Antifungal prophylaxis and treatment – current choices and strategies in children

Andreas Groll, Germany

10:55

S7.7b Diagnostic biomarkers and imaging – what is different in Pediatrics

Thomas Lehrnbecher, Germany

11:20

S7.7c Epidemiology and outcome of IFD in pediatric patients: The Southern hemisphere

Fabianne Carlesse, Brazil

11:45

S7.7d Epidemiology and outcome of IFDs in pediatric patients: The Northern Hemisphere

Emmanuel Roilidis, Greece

12:00

Lunch break, exhibition, posters

12:30

Sponsored symposium IV

13:30

Plenary session: Antifungal drug discovery comes of age

John Rex, United Kingdom

14:30

Break

15:00

Parallel session VIII

Parallel session VIII will take place from 15:00 hrs. until 16:30 hrs. and consists of six symposia.

S8.1 Host-pathogen interactions - the pathogen perspective

Convener: Bernhard Hube, Germany

15:00

S8.1a Interactions of Candida albicans with the host

Bernhard Hube, Germany

15:25

S8.1b The immunoglycobiology of fungal pathogens

Hector Mora-Montes, Mexico

15:50

S8.1c The cell wall of A.fumigatus and its impact on fungal virulence

Jean-Paul Latge, Franc

S8.2 Milestones in medical mycology: history in modern light

Convener: Luciano Polonelli, Italy

15:00

S8.2a Taxonomic benchmarks in mycotoxinogenic fungi

Robert Samson, the Netherlands

15:25

S8.2b Nystatin and the women who founded the antifungal era

Chet Cooper, USA

15:50

S8.2c History of Cryptococcus and cryptococcosis

Wanqing Liao, China

16:15

S8.2d Lahun Pyramid, more surprising treasures are revealed: fungal diversity analysis using amplicon–based metagenomic approach

Samah Soliman, Egypt

S8.3 Management of fungal resistance

Convener: Oliver Lortholary, France

15:00

S8.3a Does antifungal résistance influence the therapeutic decision during invasive candidiasis

Oliver Lortholary, France

15:25

S8.3b Antifungal therapy for C parapsilosis candidemia: who are the heroes and villains

Arnaldo Colombo, Brazil

15:50

S8.3c Infections with Scedosporium/Lomentospora from an Australian perspective - are we at the end of the road

Sharon Chen, Australia

16:15

S8.3d Voriconazole resistance and mortality in 196 Aspergillus fumigatus culture-positive patients with invasive aspergillosis

Pieter Lestrade, the Netherlands

S8.4 DNA Barcoding

Convener: Wieland Meyer, Australia

15:00

S8.4a Advances is DNA barcoding of pathogenic fungi

Wieland Meyer, Australia

15:25

S8.4b Improving DNA barcoding databases for future applications – including NGS

Vincent Robert, the Netherlands

15:50

S8.4c Applying DNA barcoding for clinical diagnosis

Gianluigi Cardinali, Italy

16:15

S8.4d Improving fungal diagnosis via dual fungal DNA barcoding

Minh Thuy Vi Hoang, Australia

S8.5 Challenges in mucosal and invasive candidiasis

Conveners: Stavroula Antonopoulou, Greece & Jesus Ortega, Spain

15:00

S8.5a - Immunity to Candida vaginitis

Flavia De Bernardis, Italy

15:25

S8.5b Management of complicated and recurrent vulvovaginal candidiasis

T.b.a.

15:50

S8.5c - Hidden echinicandin resistance induction due to abdominal candida infection

Cornelius Clancy, USA

16:15

S8.5d Identification of Candida albicans protein kinases, involved in environmental pH modulation and biofilm formation

Philipp Brandt, Germany

S8.6 ECMM Educational Symposium

Conveners: Oliver Cornely, Germany & Raoul Hebrechts, France

15:00

S8.6a Challenges in treatment of IFD in children

Thomas Lehrnbecher, Germany

15:10

S8.6b Genetic predictors of response to antifungals in IFD

Michaela Lackner, Austria

15:20

S8.6c Rare fungal infections – Experience of the German National Reference Center NRZMyk

Oliver Kurzai, Germany

15:30

S8.6d Going steady: FungiScope, a worldwide effort in researching rare fungal diseases

Danilia Seidel, Germany

15:40

S8.6e Taxonomy of Mucor

Lysett Wagner, Germany

15:50

S8.6f Challenges in clinical management of mucormycosis in children

Zoi Pana, Greece

16:00

S8.6g Rare invasive yeast infections

Luisa Durán Graeff, Chile

S8.7 New developments in dermatomycosis

15:00

S8.7a Relationship between Dermatophyte infections and occupational distribution in parts of the Savannah region of Nigeria

Aleruchi Chuku, Nigeria

15:10

S8.7b Inflammation of the gut alters the microbial balance and leads to Candida glabrata cell wall remodeling

Samir Jawhara, France

15:20

S8.7c Antifungal drug resistance of Trichophyton clinical isolates

Michel Monod, Austria

15:30

S8.7d Trichophyton mentagrophytes genotype Thailand Type 1 as causative pathogen of abscessing dermatophytoses - tinea genitalis and barbae - in Germany

Pietro Nenoff, Germany

15:40

S8.7e Survey on dermatophyte infections over the past 6 years (2012–2017) in Greece

Michael Arabatzis, Greece

15:50

S8.7f Validation of the DermaGenius® 2.0; a multiplex real-time PCR for the identification of dermatophytes species in nail, hair and skin

Giel Gaajetaan, the Netherlands

16:00

S8.7g An alarming epidemic of clinically striking and frequently relapsing steroid-modified dermatophytoses in India – a public health concern

Pietro Nenoff, Germany

16:10

S8.7h Hair fungal Infection - precise diagnosis and therapeutic effect evaluation by dermoscopy and fluorescent staining

Yuping Ran, China

16:30

Parallel session IX

Parallel session IX will take place from 16:30 hrs. until 18:00 hrs. and consists of six symposia.

S9.1 Genotyping in the NGS era

Convener: Stephane Bretagne, France

16:30

S9.1a Tracing the evolution of virulence in Cryptococcus neoformans using population sequencing

Christina Cuomo, USA

16:55

S9.1b NGS and Aspergillus fumigatus : from the environment to the clinics

John Gibbons, USA

17:20

S9.1c NGS and typing of Candida albicans: just an improvement of other typing methods?

Christophe d'Enfert, France

17:45

S9.1d Whole genome sequencing of P. brasiliensis isolates of endemic areas in Argentina and Paraguay

Maria Cattana, Argentina

S9.2 Developments in Chinese medical mycology

Convener: Ruoyu Li, China

16:30

S9.2a Anti-IFN-autoantibodies in adults with disseminated Talaromyces marneffei infections are associated with HLA-DRB1*16:02 and the Cellular Immune Responses in the patients

Cunwei Cao, China

16:55

S9.2b CARD9 deficiency and dematiaceous fungal infections

Xiaowen Wang, China

16:55

S9.2c Exploring the pathogenic roles of Fonsecaea cell wall melanin through case to bench study

Jiufeng Sun, China

17:45

S9.2d Coccidioidomycosis: Imported and possible domestic cases in China, a review from 1958 to 2017

Guanzhao Liang, China

S9.3 Dosing antifungal from the XXS to XXXL

Convener: Roger Brüggeman, the Neterlands

16:30

S9.3a T.b.a

Roger Brüggeman, the Netherlands

16:55

S9.3b from mother to child and their ontogeny with a focus on antifungal drugs

Catherine Sherwin, USA

17:20

S9.3c the heavy weight championship – impact of obesity on pharmacokinetics and dynamics

Catherijne Knibbe, the Netherlands

17:45

S9.3d Serum isavucoanzole (ISA) troughs in adult solid organ transplant patients (SOT pts) receiving prophylaxis

Hong Nuygen, USA

S9.4 MALDI-TOF in filamentous fungi

Convener: Maurizio Sanguinetti, Italy

16:30

S9.4a T.b.a.

Maurizio Sanguinetti, Italy

16:55

S9.4b Filamentous fungi MALDI-TOF identification in the clinical laboratory

Stéphane Ranque, France

17:20

S9.4c Maldi-Tof MS for the identification of filamentous fungi ; a success story outside the boundaries of the clinical lab?

Marijke Hendrickx, Belgium

17:45

S9.4d MALDI -TOF MS based identification of clinically important moulds is faster and reliable- an experience from India

Anup Gosh, India

S9.5 Recent advances in diagnosing aspergillosis

Convener: Shigeru Kohno, Japan

16:30

S9.5a How to standardize Aspergillus PCR protocols for testing various specimens

Lewis White, United Kingdom

16:55

S9.5b Aspergillus identification by volatile organic compounds release

Simona Cristescu, the Netherlands

17:20

S9.5c Detection of Invasive Pulmonary Aspergillosis in Mice Using Lung Perfusion Single-Photon Emission Computed Tomography with 99mTc-MAA

Masato Tashiro, Japan

17:45

S9.5d AsperGenius versus MycoGENIE: Comparison of two commercial Realtime PCR assays for detecting Aspergillus fumigatus in respiratory specimens

Dirk Schmidt, Germany

S9.7 Cryptococcus-host interactions

16:30

S9.7a The Hormonal Milieu and its Effects on Virulence of Cryptococcus neoformans

Tiffany Guess, USA

16:40

9.7b The effect of nutrient and temperature stress on the urease of the opportunistic pathogen Cryptococcus neoformans

Barbra Lerm, South Africa

16:50

S9.7c Titan cell production reshapes Cryptococcus neoformans cell surface composition in order to modulate and/or evade the host immune system

Liliane Mukaremera, USA

17:00

S9.7d Macrophage immune modulation by Secreted Molecules from Cryptococcus neoformans during infection

Pedro Henrique Bürgel, United Kingdom

17:10

S9.7e The impact of extracellular vesicles on Cryptococcus neoformans transmigration across brain endothelial cells

Vanessa Silva, United Kingdom

17:20

S9.7f Pathogenesis of clinical and environmental isolates of Cryptococcus neoformans and Cryptococcus gattii in human brain microvascular endothelial cells: A comparative

Shayanki Lahiri Mukhopadhyay, India

17:30

S9.7g Mismatch repair of DNA replication errors contributes to microevolution and the emergence of resistance to antifungal drugs in Cryptococcus neoformans

Kylie Boyce, Australia

17:40

S9.7h Non-lytic exocytosis of Brazilian Cryptococcus neoformans clinical isolates from macrophages

Stefania Frazão, Brazil

18:00

Closing

19:00

Congress dinner

Monday 02 Jul

Poster session V

Poster Terminal

12:15

PP1.005 - Gene co-expression analysis identifies gene clusters associated with isotropic and polarized growth in Aspergillus fumigatus conidia

Tim Baltussen, the Netherlands

12:22

PP5.034 - Composting as a resource for environmental azole resistance mutation in Aspergillus fumigatus

Bita Mousavi, France

12:29

PP5.035 - AfumID: An R Shiny application for Aspergillus fumigatus genotyping

T.R. Sewell, United Kingdom

12:36

PP5.036 - Environmental origin of clinical triazole resistance in Aspergillus fumigatus: a longitudinal field study

Sijmen Schoustra, the Netherlands

12:43

PP5.037 - Azole resistance of Aspergillus fumigatus in plant-decaying compost model

Jianhua Zhang, the Netherlands

12:50

PP5.038 - Systematic interrogation of Aspergillus fumigatus cyp51A polymorphisms for azole drug resistance

Oliver Bader, Germany

12:57

PP5.039 - Fungal contamination in horse stables and risk of equine aspergillosis: results of a pilot study in France

Jacques Guillot, France

13:04

PP5.040 - Chronic pulmonary aspergillosis in active pulmonary tuberculosis patients in Jakarta, Indonesia

Findra Setianingrum, United Kingdom

Poster Terminal 2

12:15

PP5.073 - The Kennedy pathway can increase the virulence of Candida albicans

Todd Reynolds, USA

12:22

PP5.074 - Azole resistance and modulation of macrophage pro-inflammatory response by Candida albicans MAM33

N. Chauhan, USA

12:29

PP5.075 - Understanding the function of Pga15 family in Candida albicans pathobiology

Elham Khatrawi, United Kingdom

12:36

PP5.076 - Studying the role of CgMIP1 in the evolution of Candida glabrata during adaption to the human host

Sofia Siscar-Lewin, Germany

12:43

PP5.077 - Addressing the Most Neglected Diseases through an Open Research Model: the Discovery of Fenarimols as Novel Drug Candidates for Eumycetoma

Wilson Lim, the Netherlands

12:50

PP5.078 - Establishing burn wound models for infection with Candida spp

Christin Von Mueller, Germany

12:57

PP5.079 - T2Candida and blood culture results predict mortality among patients with candidemia

Cornelius Clancy, USA

13:04

PP5.080 - A Simple and Noninvasive Zebrafish Egg Infection Model for Studying Pathogenic Yeasts

Hsiu-Jung Lo, Taiwan

Poster Terminal 4

12:15

PP5.113 - Predictive value of a nasopharyngeal aspirate sample for diagnosis of pulmonary Pneumocystis in infants: A prospective autopsy study

Sergio Vargas, Chile

12:22

PP5.114 - Comparative analysis of yeast species identification using phenotypic methods and real-time PCR

Tatiana Priputnevich, Russia

12:29

PP5.115 - Comparing small and high volume sample fungal with routine culture for improved yield of mold from sputa

Joveria Farooqi, Pakistan

12:36

PP5.116 - Molecular diagnostic strategies in cancer patients with suspected respiratory mold infections

V. Rickerts, Germany

12:43

PP5.117 - Agreement between phenotypic and molecular method for the identification of filamentous molds: Experience from a routine diagnostic laboratory from Pakistan

Seema Irfan, Pakistan

12:50

PP5.118 - Molecular epidemiology, risk factor analysis and Comparison of diagnostic methods for Rapid Diagnosis of Fungal Pneumonia in Critically ill Cirrhotics

Pratibha Kale, India

12:57

PP5.119 - Pneumocystis jirovecii pneumonia in patients with hematological diseases after hematopoietic stem cell transplantation and chemotherapy

Yuliya Rogacheva, Russia

13:04

PP5.120 - Molecular characterization, virulence determinants and antifungal susceptibility testing of Trichosporon asahii isolates from Nepal

Niranjan Nayak, Nepal

Poster Terminal 5

12:15

PP5.153 - New insights on fibrogenesis and serum biomarkers for pulmonary fibrosis in paracoccidioidomycosis

James Venturini, Brazil

12:22

PP5.154 - Human and veterinary blastomycosis caused by Blastomyces helicus and B. percursus identified among global fungal collections

Ilan Schwartz, Canada

12:29

PP5.155 - Talaromyces marneffei cell wall glucans: their role in recognition by host cell and pathogenicity

Aakash Gupta, Australia

12:36

PP5.156 - Comparative genomics of Rhinocladiella mackenziei

A. Ahmed, Saudi Arabia

12:43

PP5.157 - Evaluation of Quantitative Real-Time PCR and Platelia Galactomannan Assay for Diagnosis of Disseminated Talaromyces marneffei Infection

Cunwei Cao, China

12:50

PP5.158 - Susceptibility to hydrogen peroxide and molecular characterization of catalase encoding genes in different Sporothrix species

Cinzia Barresi, Italy

12:57

PP5.159 - Tuberculosis and histoplasmosis diagnosis among people living with HIV/AIDS: the impact of using rapid diagnostics tests in Panama, 2017

Diego Caceres, USA

13:04

PP5.160 -Veterinary mycosis in a tropical country

Alejandra Calderón-Hernández, Costa Rica

Poster Terminal 6

12:15

PP5.193 - Mating type and population genomics in Malassezia

Qi-Ming Wang, China

12:22

PP5.194 - Morbidity of fungal infections caused by Malassezia furfur in neonatal intensive care units

Tatiana Priputnevich, Russia

12:29

PP5.195 - Molecular identification and speciation of Malassezia and its susceptibility pattern

Romald Packia Nancy, India

12:36

PP5.196 - Activity of investigational tetrazole antifungals VT-1161 and VT-1598 against a collection of characterized fluconazole resistant Candida parapsilosis clinical isolates

Jeffrey Rybak, USA

12:43

PP5.197 - Polymerase chain reaction (PCR) diagnosis and identification of mucormycosis in patients with suspected invasive fungal infection

T. Shokohi, Iran

12:50

PP5.198 - Immunopathogenesis and virulence of invasive mucormycosis differs considerably between mucormycete species

Cornelia Speth, Austria

12:57

PP5.199 - Posaconazole prophylaxis in patients with acute myeloid leukemia: A real life experience from a prospective multicenter observational study

Gokhan Metan, Turkey

13:04

PP5.200 - Visceral mycoses in autopsied cases in Japan from 1989 to 2013: increasing prevalence of cases with mucormycetes

Yuhko Suzuki, Japan